LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 298.95 -5.05 (-1.66%) (As of 09/6/2024 12:05 PM ET) Add Compare Share Share Today's Range 294▼ 302.2550-Day Range 296▼ 38252-Week Range 180▼ 430Volume14,502 shsAverage Volume23,847 shsMarket Capitalization£314.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get MaxCyte alerts: Email Address Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About MaxCyte Stock (LON:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesSeptember 6 at 5:15 AM | americanbankingnews.comMaxCyte (LON:MXCT) Stock Crosses Below Fifty Day Moving Average of $332.41August 21, 2024 | finance.yahoo.comMaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five yearsSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 13, 2024 | finance.yahoo.comStratec SE (SRBZF)August 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for MaxCyte on Strong SPL Revenue Growth and Solid Financial PositionAugust 7, 2024 | msn.comMaxCyte, Inc. (NASDAQ:MXCT) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | markets.businessinsider.comMaxCyte earnings preview: what to expectMay 23, 2024 | finance.yahoo.comWith 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional ownersSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…May 13, 2024 | seekingalpha.comMaxCyte, Inc. (MXCT) Q1 2024 Earnings Call TranscriptMay 12, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call TranscriptApril 4, 2024 | finance.yahoo.comNotice of Annual General Meeting of Vicore Pharma Holding AB (publ)March 14, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | finance.yahoo.comMaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five yearsMarch 12, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023March 11, 2024 | markets.businessinsider.comMaxCyte earnings: here's what Wall Street expectsMarch 11, 2024 | benzinga.comMaxCyte Earnings PreviewJanuary 27, 2024 | msn.comMaxCyte Inc Announces Cenk Sumen’s Transition and Severance TermsSee More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryBusiness Services Current SymbolLON:MXCT CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-35,430,000.00 Net Margins-77.97% Pretax MarginN/A Return on Equity-15.33% Return on Assets-11.07% Debt Debt-to-Equity Ratio8.37 Current Ratio14.31 Quick Ratio14.38 Sales & Book Value Annual Sales£45.44 million Price / Sales6.91 Cash FlowGBX 151.60 per share Price / Cash Flow1.97 Book ValueGBX 211 per share Price / Book1.42Miscellaneous Outstanding Shares105,090,000Free FloatN/AMarket Cap£314.17 million OptionableNot Optionable Beta1.13 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Maher Masoud (Age 48)President, CEO, Secretary & Director Comp: $484.7kMr. Douglas Arthur Doerfler (Age 68)Founder Comp: $950.01kMr. Douglas J. Swirsky CFA (Age 55)CPA, Chief Financial Officer Mr. Jay GelfmanSenior Vice President of OperationsMr. Ronald Evan Holtz CPA (Age 66)Ph.D., Executive Vice President of Administration Comp: $514.26kMr. Sean MenarguezDirector of Investor RelationsMr. David SandovalSenior Vice President & General CounselMr. Thomas Michael Ross (Age 63)Executive Vice President of Global Sales Mr. Jack HorganVice President of Corporate DevelopmentMs. Jill MayerSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsHeraldLON:HRIResolute MiningLON:RSGLookersLON:LOOKPayPointLON:PAYOcean WilsonsLON:OCNView All CompetitorsInsidersJohn JohnstonSold 5,000 sharesTotal: £2.21 M ($441.00/share)John JohnstonSold 200 sharesTotal: £90,600.00 ($453.00/share)View All Insider Transactions MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 352.50 on January 1st, 2024. Since then, MXCT shares have decreased by 15.2% and is now trading at GBX 298.95. View the best growth stocks for 2024 here. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO). This page (LON:MXCT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MXCT Stock Alerts